2 resultados para MALARIA VACCINE CANDIDATE
em Instituto Politécnico do Porto, Portugal
Resumo:
We study a fractional model for malaria transmission under control strategies.Weconsider the integer order model proposed by Chiyaka et al. (2008) in [15] and modify it to become a fractional order model. We study numerically the model for variation of the values of the fractional derivative and of the parameter that models personal protection, b. From observation of the figures we conclude that as b is increased from 0 to 1 there is a corresponding decrease in the number of infectious humans and infectious mosquitoes, for all values of α. This means that this result is invariant for variation of fractional derivative, in the values tested. These results are in agreement with those obtained in Chiyaka et al.(2008) [15] for α = 1.0 and suggest that our fractional model is epidemiologically wellposed.
Resumo:
The most effective therapeutic option for managing nonmuscle invasive bladder cancer (NMIBC), over the last 30 years, consists of intravesical instillations with the attenuated strain Bacillus Calmette-Gu´erin (the BCG vaccine). This has been performed as an adjuvant therapeutic to transurethral resection of bladder tumour (TURBT) and mostly directed towards patients with highgrade tumours, T1 tumours, and in situ carcinomas. However, from 20% to 40% of the patients do not respond and frequently present tumour progression. Since BCG effectiveness is unpredictable, it is important to find consistent biomarkers that can aid either in the prediction of the outcome and/or side effects development. Accordingly, we conducted a systematic critical review to identify themost preeminent predictive molecular markers associated with BCG response. To the best of our knowledge, this is the first review exclusively focusing on predictive biomarkers for BCG treatment outcome. Using a specific query, 1324 abstracts were gathered, then inclusion/exclusion criteria were applied, and finally 87 manuscripts were included. Several molecules, including CD68 and genetic polymorphisms, have been identified as promising surrogate biomarkers. Combinatory analysis of the candidate predictive markers is a crucial step to create a predictive profile of treatment response.